MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · Real-Time Price · USD

16.66

-0.19 (-1.13%)

At close: Apr 28, 2026, 4:00 PM EDT

16.76

+0.10 (0.59%)

After-hours: Apr 28, 2026, 7:33 PM EDT

MLTX Employees

MoonLake Immunotherapeutics had 130 employees as of December 31, 2025. The number of employees increased by 30 or 30.00% compared to the previous year.

Employees

130

Change (1Y)

Growth (1Y)

30.00%

Revenue / Employee

n/a

Profits / Employee

-$1,748,600

Market Cap

1.19B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2025	130	30	30.00%
Dec 31, 2024	100	50	100.00%
Dec 31, 2023	50	30	150.00%
Dec 31, 2022	20	-	-

Related Stocks

Company Name	Employees
AbCellera Biologics	562
Pharming Group	407
UroGen Pharma	291
uniQure	221
EyePoint	214
MapLight Therapeutics	133
DBV Technologies	117
GH Research	73

Employee Rankings

MLTX News

4 weeks ago - MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting - GlobeNewsWire
2 months ago - MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain - Benzinga
2 months ago - MoonLake Immunotherapeutics Transcript: Investor Day 2026 - Transcripts
2 months ago - ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer - GlobeNewsWire
3 months ago - MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day - GlobeNewsWire
3 months ago - Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares - GlobeNewsWire
3 months ago - Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering - GlobeNewsWire
3 months ago - MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars - Benzinga

More News